Bortezomib: A novel chemotherapeutic agent for hematologic malignancies
- 1 July 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 65 (13), 1221-1231
- https://doi.org/10.2146/ajhp070272
Abstract
Purpose. The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage and administration, place in therapy, and cost of bortezomib in the treatment of multiple myeloma and mantle cell lymphoma are reviewed.Keywords
This publication has 35 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Ubiquitin domain proteins in diseaseBMC Biochemistry, 2007
- Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysisJNCI Journal of the National Cancer Institute, 2007
- Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivinMolecular Cancer Therapeutics, 2005
- The ubiquitin–proteasome system and cancerEssays in Biochemistry, 2005
- Multiple Myeloma: Diagnosis and TreatmentMayo Clinic Proceedings, 2005
- Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day CycleJournal of Clinical Oncology, 2005
- Suppression of TNF-α-Induced Apoptosis by NF-κBScience, 1996
- An Essential Role for NF-κB in Preventing TNF-α-Induced Cell DeathScience, 1996
- The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κBCell, 1994